186 related articles for article (PubMed ID: 17228314)
1. A CD46-binding chimpanzee adenovirus vector as a vaccine carrier.
Tatsis N; Blejer A; Lasaro MO; Hensley SE; Cun A; Tesema L; Li Y; Gao GP; Xiang ZQ; Zhou D; Wilson JM; Ertl HC
Mol Ther; 2007 Mar; 15(3):608-17. PubMed ID: 17228314
[TBL] [Abstract][Full Text] [Related]
2. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors.
McCoy K; Tatsis N; Korioth-Schmitz B; Lasaro MO; Hensley SE; Lin SW; Li Y; Giles-Davis W; Cun A; Zhou D; Xiang Z; Letvin NL; Ertl HC
J Virol; 2007 Jun; 81(12):6594-604. PubMed ID: 17428852
[TBL] [Abstract][Full Text] [Related]
3. Adenovirus serotype 35 vector-induced innate immune responses in dendritic cells derived from wild-type and human CD46-transgenic mice: Comparison with a fiber-substituted Ad vector containing fiber proteins of Ad serotype 35.
Sakurai F; Nakashima K; Yamaguchi T; Ichinose T; Kawabata K; Hayakawa T; Mizuguchi H
J Control Release; 2010 Dec; 148(2):212-8. PubMed ID: 20800630
[TBL] [Abstract][Full Text] [Related]
4. Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers.
Pinto AR; Fitzgerald JC; Giles-Davis W; Gao GP; Wilson JM; Ertl HC
J Immunol; 2003 Dec; 171(12):6774-9. PubMed ID: 14662882
[TBL] [Abstract][Full Text] [Related]
5. Chimpanzee-origin adenovirus vectors as vaccine carriers.
Tatsis N; Tesema L; Robinson ER; Giles-Davis W; McCoy K; Gao GP; Wilson JM; Ertl HC
Gene Ther; 2006 Mar; 13(5):421-9. PubMed ID: 16319951
[TBL] [Abstract][Full Text] [Related]
6. Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice.
Dicks MD; Spencer AJ; Coughlan L; Bauza K; Gilbert SC; Hill AV; Cottingham MG
Sci Rep; 2015 Nov; 5():16756. PubMed ID: 26576856
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus serotype 35 vector-mediated transduction into human CD46-transgenic mice.
Sakurai F; Kawabata K; Koizumi N; Inoue N; Okabe M; Yamaguchi T; Hayakawa T; Mizuguchi H
Gene Ther; 2006 Jul; 13(14):1118-26. PubMed ID: 16541121
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell maturation, but not CD8+ T cell induction, is dependent on type I IFN signaling during vaccination with adenovirus vectors.
Hensley SE; Giles-Davis W; McCoy KC; Weninger W; Ertl HC
J Immunol; 2005 Nov; 175(9):6032-41. PubMed ID: 16237098
[TBL] [Abstract][Full Text] [Related]
9. Antigen encoded by vaccine vectors derived from human adenovirus serotype 5 is preferentially presented to CD8+ T lymphocytes by the CD8α+ dendritic cell subset.
Suleman M; Galea S; Gavard F; Merillon N; Klonjkowski B; Tartour E; Richardson J
Vaccine; 2011 Aug; 29(35):5892-903. PubMed ID: 21723900
[TBL] [Abstract][Full Text] [Related]
10. Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector.
Hensley SE; Cun AS; Giles-Davis W; Li Y; Xiang Z; Lasaro MO; Williams BR; Silverman RH; Ertl HC
Mol Ther; 2007 Feb; 15(2):393-403. PubMed ID: 17235319
[TBL] [Abstract][Full Text] [Related]
11. CD46 represents a target for adenoviral gene therapy of malignant glioma.
Ulasov IV; Tyler MA; Zheng S; Han Y; Lesniak MS
Hum Gene Ther; 2006 May; 17(5):556-64. PubMed ID: 16716112
[TBL] [Abstract][Full Text] [Related]
12. Generation of an adenoviral vaccine vector based on simian adenovirus 21.
Roy S; Zhi Y; Kobinger GP; Figueredo J; Calcedo R; Miller JR; Feldmann H; Wilson JM
J Gen Virol; 2006 Sep; 87(Pt 9):2477-2485. PubMed ID: 16894185
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of adenovirus vectors containing serotype 35 fibers for vaccination.
DiPaolo N; Ni S; Gaggar A; Strauss R; Tuve S; Li ZY; Stone D; Shayakhmetov D; Kiviat N; Touré P; Sow S; Horvat B; Lieber A
Mol Ther; 2006 Apr; 13(4):756-65. PubMed ID: 16461009
[TBL] [Abstract][Full Text] [Related]
14. Replication-competent Ad11p vector (RCAd11p) efficiently transduces and replicates in hormone-refractory metastatic prostate cancer cells.
Sandberg L; Papareddy P; Silver J; Bergh A; Mei YF
Hum Gene Ther; 2009 Apr; 20(4):361-73. PubMed ID: 19199789
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting.
Ni S; Gaggar A; Di Paolo N; Li ZY; Liu Y; Strauss R; Sova P; Morihara J; Feng Q; Kiviat N; Touré P; Sow PS; Lieber A
Cancer Gene Ther; 2006 Dec; 13(12):1072-81. PubMed ID: 16874361
[TBL] [Abstract][Full Text] [Related]
16. Hexon-modified recombinant E1-deleted adenovirus vectors as dual specificity vaccine carriers for influenza virus.
Zhou D; Wu TL; Emmer KL; Kurupati R; Tuyishime S; Li Y; Giles-Davis W; Zhou X; Xiang Z; Liu Q; Ratcliffe SJ; Ertl HC
Mol Ther; 2013 Mar; 21(3):696-706. PubMed ID: 23229092
[TBL] [Abstract][Full Text] [Related]
17. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier.
Xiang ZQ; Gao GP; Reyes-Sandoval A; Li Y; Wilson JM; Ertl HC
J Virol; 2003 Oct; 77(20):10780-9. PubMed ID: 14512528
[TBL] [Abstract][Full Text] [Related]
18. The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens.
Schirmbeck R; Reimann J; Kochanek S; Kreppel F
Mol Ther; 2008 Sep; 16(9):1609-16. PubMed ID: 18612271
[TBL] [Abstract][Full Text] [Related]
19. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
[TBL] [Abstract][Full Text] [Related]
20. The effect of adenovirus-specific antibodies on adenoviral vector-induced, transgene product-specific T cell responses.
Small JC; Haut LH; Bian A; Ertl HC
J Leukoc Biol; 2014 Nov; 96(5):821-31. PubMed ID: 25082150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
